← Back to Search

Mobile Epilepsy Education Package for Knowledge, Attitudes, and Practices (KAP)

N/A
Waitlist Available
Led By Kenneth Alexis Myers, MD PhD FRCPC
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Parents/caregivers whose children are between 1-17 years old;
Parents/caregivers whose child was diagnosed with epilepsy at least 2 months ago;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 weeks
Awards & highlights

Study Summary

Background. Following a childhood diagnosis of epilepsy, children and their families encounter significant concerns about the disease trajectory, side effects of anti-seizure medications, and long-term prognosis. The multitude of uncertainties can cause significant anxiety in the family, often within the context of limited supports and resources. Epilepsy education can help address these concerns, mitigating the development of anxiety, ultimately leading to better patient-, family- and system-level outcomes. Globally, the MEEP is the only mobile application providing education, monitoring of symptoms, and tracking of medical appointments. The original MEEP was developed, tested, and integrated into practice in Turkey; the investigators will now evaluate the efficacy of an English and French version of the MEEP for families of children with epilepsy in Canada. A two-group, single-center, randomized controlled intervention trial with 1:1 allocation ratio will be conducted in the Pediatric Neurology Clinic of the Montreal Children's Hospital. Seventy-two caregivers of children with epilepsy (intervention=36, control= 36), aged 1-17 years and treated at the study site will be eligible. Family Introduction Form, Epilepsy Information Scale for Parents and Parental Anxiety Scale for Seizures will be used to collect data at baseline and 3 weeks post-delivery of the 7-week intervention. The MEEP consists of 2 parts. The first part entails the delivery of the educational content of the MEEP, and the second part consists of a "Parental Monitoring Section." Comparator. The control group will continue to benefit from the standard educational services provided by the study site.

Eligible Conditions
  • Knowledge, Attitudes, and Practices (KAP)
  • Epilepsy
  • Anxiety
  • Childhood Epilepsy

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in epilepsy knowledge after 1 month of use of the Mobile Epilepsy Education Package
Secondary outcome measures
Change in epilepsy anxiety after 1 month of use of the Mobile Epilepsy Education

Trial Design

2Treatment groups
Experimental Treatment
Group I: Standard care consisting of epilepsy educationExperimental Treatment1 Intervention
Standard care consisting of epilepsy education and support offered at the study setting by members of the Pediatric Neurology Clinic was chosen as the comparator and serves as the control group.
Group II: Mobile Epilepsy Education PackageExperimental Treatment1 Intervention
The Mobile Epilepsy Education Package (MEEP) consists of 2 parts. The first part entails the delivery of the "MEEP education", and the second part consists of the "Parental Monitoring Section". The intervention group will use MEEP for 4 weeks.

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
449 Previous Clinical Trials
159,774 Total Patients Enrolled
The Scientific and Technological Research Council of TurkeyOTHER
128 Previous Clinical Trials
17,600 Total Patients Enrolled
Kenneth Alexis Myers, MD PhD FRCPCPrincipal InvestigatorRI-MUHC, Montreal Children's Hospital, McGill University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~48 spots leftby Sep 2026